golimumab human monoclonal antibody used immunosuppressive medication sold brand name simponi golimumab targets tumor necrosis factor alpha tnfalpha proinflammatory hence tnf inhibitor profound reduction creactive protein crp levels interleukin intercellaular adhesion molecules matrix metalloproteinase vascular endothelial growth factor vegf demonstrates golimumab effective modulator inflammatory markers bone world health organizations list essential golimumab developed janssen biotech inc formerly centocor biotech inc also markets product united states janssen pharmaceutical companies market simponi canada central south america middle east africa asia pacific europe russia turkey simponi distribution rights held scheringplough ireland company subsidiary merck co inc japan indonesia taiwan distribution rights held mitsubishi tanabe pharma european medicines agency ema approved use golimumab treatment rheumatoid arthritis psoriatic arthritis ankylosing golimumab approved treatment us food drug administration fda well european medicines agency ema treatment ulcerative golimumab either used via self administered subcutaneous injection intravenous golimumab approved united monthly subcutaneous treatment adults moderately severely active rheumatoid arthritis psoriatic arthritis juvenile idiopathic arthritis ankylosing common adverse reactions incidence upper respiratory tract infection nasopharyngitis injection site golimumab binds soluble transmembrane forms tnfα antibody isolated hybridoma clone produced transgenic mice immunized human tnfα golimumabsecreting clone selected assayed human light heavy chains tnfαbinding commercial product produced recombinant cell line cultured continuous large doubleblind randomized controlled trials patients rheumatoid arthritis shown golimumab combination methotrexate effective methotrexate clinically indicated golimumab estimated moderate costeffective treatment option national institutes health care excellence nice stated treatment golimumab recommended ra patients failed prior tnfi unlike tnfi treatments adalimumab certolizumab pegol reported cases druginduced lupuslike syndrome preliminary evidence golimumab treatment option ocular immune activation dostarlimab ibalizumab httpsenwikipediaorgwikigolimumab